Nurix Therapeutics (NRIX) Reports First Clinical Evidence of CNS Activity of NX-5948
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Nurix (NRIX) PT Raised to $23 at RBC Capital
April 11, 2024 6:28 AM EDTRBC Capital analyst Gregory Renza raised the price target on Nurix (NASDAQ: NRIX) to $23.00 (from $22.00) while maintaining a Outperform rating.
The analyst comments "The 1Q fiscal 24 EPS report recapped NRIX's recent partnership extensions that expand the company's TPD footprint in the I&I space... More
JPMorgan Takeaways on Nurix (NRIX) Q1 Earnings
April 10, 2024 12:32 PM EDTJPMorgan analyst Eric Joseph reiterated an Overweight rating and $30.00 price target on Nurix (NASDAQ: NRIX).
The analyst comments "Nurix reported a 1Q loss per share of $0.76, with takeaways from the print being incremental to those from the companys AACR presentation, updated collaboration with SNY, and our recent discussion with mgmt. On NX-5948 (BTK degrader for B-cell malignancies), the... More
Nurix Therapeutics (NRIX) Announces Extension of Strategic Collaboration with Sanofi (SNY) to Develop Novel Targeted Protein Degraders of STAT6
April 9, 2024 7:13 AM EDTNurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, announced today an extension of the ongoing research program with Sanofi for STAT6 (signal transducer and activator of transcription 6). STAT6 is a key drug target in type 2 inflammation.
STAT6 is a key transcription factor within the IL-4/IL-13 signaling pathways which act as drivers of inflammation in allergic conditions. These conditions are currently treated with injectable monoclonal antibody therapies, which are designed to impede IL-4/IL-13 signaling, said... More
